ClinicalTrials.gg
RecruitingNCT05367700Updated Jan 13, 2023

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

A Phase 1 interventional study of HS-10382(Part 1: Dose escalation) and HS-10382(Part 2: Dose expansion) in CML, Chronic Phase and CML, Accelerated Phase, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-01-13.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Leukemia, Myeloid, Chronic-Phase with a site in China — 3 open to participants now, 4 under way, 1 of them phase 3. Leukemia, Myeloid, Chronic-Phase · China.

Planned enrollment
7th of 13
108 · median 108
Started
2022
with 2 others
Phase 1
2 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
3 of 13
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Among the 13 studies in Leukemia, Myeloid, Chronic-Phase with a site in China, this one is the 7th largest by planned enrollment, is one of 3 that started in 2022, is one of 2 in phase 1, and was the 13th registered.

Leukemia, Myeloid, Chronic-Phase

439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.

Browse Leukemia, Myeloid, Chronic-Phase studies →

Open to participants now

3 of the 13 studies in Leukemia, Myeloid, Chronic-Phase with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Leukemia, Myeloid, Chronic-Phase with a site in China, or all of them as a file.
02

Study summary

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.

Read the detailed description

This is an open-label, multicenter, dose-escalation and expansion, first-in-human study in participants of CML with T315I mutation or without T315I mutation in chronic phase/accelerate phase(CP/AP). This study will consist of two parts: A part 1 dose escalation stage and a part 2 dose expansion stage. The objectives of this study are to evaluate the safety, tolerability, PK and preliminary anti-CML activity, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum applicable dose (MAD) of HS-10382. Participants with CML-CP/AP are eligible for dose escalation study if they had resistance to or unacceptable side effect from BCR-ABL1 TKIs. After determination of the MTD or the MAD for CML patients, dose expansion will be undertaken to further evaluate the efficacy and safety of HS-10382 in patients with CML-CP. All patients will be carefully followed for adverse events during the study treatment and for 28 days after the last dose of study drug. Subjects of this study will be permitted to continue therapy with assessments for progression if the product is well tolerated and the subject has stable disease or better.

03

Conditions studied

  • CML, Chronic Phase
  • CML, Accelerated Phase

Keywords

  • CML-CP/AP
  • HS-10382
  • BCR-ABL TKI
  • Phase I
  • Allosteric inhibitor
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form.
  2. Men or women aged more than or equal to (≥) 18 years, and less than (\<) 75 years.
  3. CML-CP/AP patients with the Ph chromosome or BCR-ABL1 fusion genes.
  4. Patient with CML-CP/AP who are resistant to or intolerant to previous TKIs therapy.
  5. performance status of 0-2.
  6. ≥ 12 weeks.
  7. Men or women should be using adequate measures throughout the study; Females should not be breastfeeding at the time of screening, during the study and until 6 months after completion of the study.
  8. Females must have evidence of non-.

Exclusion criteria

Exclusion Criteria:

  1. CML-CP patients who have acquired CCyR and have not lost it.
  2. Patients with CML-CP who have progressed to AP or blast phase(BP.)
  3. Patients with CML-AP who have obtained CHR or no evidence of CML in peripheral blood.
  4. Patients with CML-AP who have progressed to BP.
  5. Previous treatment with a BCR-ABL1 TKI allosteric inhibitor .
  6. Impaired cardiac function including any one of the following:

    1. Resting interval (QTc) > 470 ms obtained from (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).
    2. Any abnormalities in rhythm, conduction, or morphology of the resting ECG.
    3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events,
    4. (LVEF) ≤ 50%.
    5. During screening period, ECG examination showed average heart rate \<50 beats per minute.
    6. Myocardial infarction occurred within 6 months of the first scheduled dose of HS-10382.;
    7. Congestive heart failure occurred within 6 months of the first scheduled dose of HS-10382.;
    8. Uncontrollable angina.
  7. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  8. Any severe or uncontrolled systemic diseases (i.e. uncontrolled hypertension or diabetes).
  9. Clinically severe gastrointestinal dysfunction that may affect drug intake, transport or absorption.
  10. Severe infection within 4 weeks prior to the first scheduled dose of HS-10382.
  11. History of significant congenital or acquired bleeding disorders unrelated to CML.
  12. Inadequate other organ function.
  13. History of other .
  14. History of to any active or inactive ingredient of HS-10382.
  15. History of neuropathy or mental disorders, including epilepsy and dementia.
  16. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    HS-10382 (Part 1: Dose escalation)

    There are five escalation dose cohorts.

    Drug: HS-10382(Part 1: Dose escalation)

  • Experimental
    HS-10382 (Part 2: Dose expansion)

    The recommended dose from the dose-escalation stage and other potential doses will be further explored.

    Drug: HS-10382(Part 2: Dose expansion)

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1(Dose escalation): Maximum tolerated dose (MTD) for HS-10382

    MTD was defined as the previous dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT.

    Time frame: From the single dose to the last dose of the first cycle as 28days of multiple dosing (35days).

  2. Part 2(Dose expansion): Major cytogenetic response (MCyR) rate at 6 months

    MCyR is the proportion of patients achieving Complete cytogenetic response (CCyR: defined as 0% Philadelphia chromosome-positive \[Ph+\] metaphases by cytogenetic analysis of bone marrow) and Partial Cytogenetic Response (PCyR: defined as \>0% to 35% Ph+ metaphases by cytogenetic analysis of bone marrow).

    Time frame: 6 months

Secondary outcomes

  1. Incidence and severity of treatment-emergent adverse events

    Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, and NCI CTCAE v5.0.

    Time frame: From baseline until 28 days after the last dose.

  2. Observed maximum plasma concentration (Cmax) after single dose of HS-10382

    From pre-dose to 120 hours after single dose on Day 1

    Time frame: In the study of single-dose, Cmax will be obtained following administration of a single oral dose of HS-10382 on Day 1 to Day 6.

  3. Time to reach maximum plasma concentration (Tmax) after single dose of HS-10382

    In the study of single-dose, Tmax will be obtained following administration of a single oral dose of HS-10382 on Day 1 to Day 6.

    Time frame: From pre-dose to 120 hours after single dose on Day 1

  4. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10382

    Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: From pre-dose to 120 hours after single dose on Day 1

  5. Hematologic response

    Hematologic response will be assessed by complete blood count (CBC) and physical examination at each visit.

    Time frame: at screening and 28th day of cycle 1,2,3,4,5,6,9 and 12.

  6. Molecular response

    Molecular response will be assessed by BCR-ABL1 transcript level as measured by RQ-PCR.

    Time frame: at screening and 28th day of cycle 3, 6, 9 and 12.

  7. Cytogenetic response

    Cytogenetic response (CyR) is based on the prevalence of Ph+ cells in metaphase from bone marrow (BM) sample.

    Time frame: at screening and 28th day of cycle 3, 6, 9 and 12.

  8. Event-free survival (EFS)

    EFS is defined as the time from the date of first dose to the earliest occurrence of the following events: death due to any cause ; loss of CHR ,loss of PCyR ;loss of CCyR ; discontinuation of study treatment due to AE or treatment failure ; progression to AP/BC .

    Time frame: up to 24 months

  9. Progression-free survival (PFS)

    PFS is defined as the time from the date of first dose to the earliest occurrence of progression to AP/BC or death from any cause.

    Time frame: up to 24 months

  10. Overall survival (OS)

    OS is defined as the time from the date of first dose to the date of death from any cause.

    Time frame: up to 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Dec 2024, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2022
First posted
May 10, 2022
StartActual
Apr 28, 2022
Primary completionEst.
Dec 30, 2024
CompletionEst.
Sep 30, 2026
Last update
Jan 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05367700
Responsible party
Sponsor
First posted
May 10, 2022
Start date
Apr 28, 2022
Primary completion
Dec 30, 2024 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jan 13, 2023

Study contacts

Yu Hu
Contact
dr_huyu@126.com
13986183871
Yu Hu
principal investigator · Wuhan Union Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Embibatinib

Start the discussion